Use of sodium–glucose cotransporter 2 inhibitor in heart failure: a real-world study
SGLT2i use predominates in patients with HFrEF and in those with a high comorbidity burden. Adherence and persistence were similar to or even better than those reported in other real-world evidence studies.
Authors
- Jorge Enrique Machado‐Alba (ORCID: https://orcid.org/0000-0002-8455-0936)
- Luis Fernando Valladales‐Restrepo (ORCID: https://orcid.org/0000-0002-4245-0101)
- Ana Sofia Franco-Carvajal
- María Fernanda Lerma-Barco
- Daniela Torrente-López
- Carlos Manuel Bedoya-Toro
Institutions
- Technological University of Pereira (CO)
- Institución Universitaria Visión de las Américas (CO)
Publication Details
- Journal
- Expert Review of Cardiovascular Therapy
- Published
- 2025-11-30
- DOI
- https://doi.org/10.1080/14779072.2025.2598405
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00